The 86.3m NPAT is after insurance claim settlement of 86.0m and should be taken out if you are looking at underlying performance. The NPAT was actually b/e, operating cash flow was negative for FY15/16.
Not saying it's not a bad buy, I havent looked at it beyond checking what you had up there as it seemed like too much of a no-brainer.
